# Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)

> **NCT02437500** · — · APPROVED_FOR_MARKETING · sponsor: **Seres Therapeutics, Inc.**

## Conditions studied

- Clostridioides Difficile Infection

## Interventions

- **BIOLOGICAL:** SER-109

## Key facts

- **NCT ID:** NCT02437500
- **Lead sponsor:** Seres Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437500, "Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02437500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*